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ABSTRACT: The protein kinase ERK5 (MAPK7) is an emerging drug target for a variety of indications, in particular for cancer
where it plays a key role mediating cell proliferation, survival, epithelial−mesenchymal transition, and angiogenesis. To date, no
three-dimensional structure has been published that would allow rational design of inhibitors. To address this, we determined the
X-ray crystal structure of the human ERK5 kinase domain in complex with a highly speciﬁc benzo[e]pyrimido[5,4-b]diazepine-
6(11H)-one inhibitor. The structure reveals that speciﬁc residue diﬀerences in the ATP-binding site, compared to the related
ERKs p38s and JNKs, allow for the development of ERK5-speciﬁc inhibitors. The selectivity of previously observed ERK5
inhibitors can also be rationalized using this structure, which provides a template for future development of inhibitors with
potential for treatment of disease.
■ INTRODUCTION
ERK5, also known as MAPK7 and BMK1 (big map kinase),
was ﬁrst identiﬁed in 1995.1,2 It is the terminal kinase in the
ERK5 signaling pathway that involves MEKK2/MEKK3 and
MEK5, a pathway required for angiogenesis and placental
development3−5 and for neural diﬀerentiation in Xenopus
embryos,6 although experiments in mice show that ERK5
knockout does not block neural development but does aﬀect
the number of interneurons.7 Among other stimuli, ERK5 is
activated by epidermal growth factor (EGF).8 It is expressed in
many cell types1,2,9 and phosphorylates various substrates
including c-Fos and Fra-1,10 Sap1A,11 myocyte enhancer factor
2 (MEF2),12 MEF2C,13 and c-Myc.14 Structurally, ERK5 diﬀers
from other MAPK family members in that it has an extended
C-terminal region (hence, the name big map kinase), which
may have an autoinhibitory role.9 The C-terminus also contains
a transcriptional activation domain that interacts with
MEF2D15 and that enhances the transactivation activity of
activator protein 1 (AP-1), after it has itself been
autophosphorylated by the activated ERK5 kinase domain.16
The region N-terminal to the kinase domain contains
sequences for targeting to the cytoplasm, while in the C-
terminal region there is a nuclear localization sequence
(residues 505−539).17 ERK5 is found in both cytoplasmic
and nuclear locations.9
The kinase domain itself has closest similarity to the kinase
domains of MAPK3 (ERK1, 51%), MAPK1 (ERK2, 51%),
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MAPK11 (p38β, 47%), MAPK14 (p38α, 46%), MAPK13
(p38δ, 43%), NLK (nemo-like kinase, 43%), and MAPK12
(p38γ, 38%). Crystal structures have so far been determined for
all human p38 and JNK MAPKs. Of the ERK family, there are
structures for ERK1,18 ERK2,19 and ERK3 (PDB code 2I6L,
unpublished). The only MAP kinase structures currently
remaining unsolved are ERK5, ERK7, and the atypical MAP
kinase ERK4. (Atypical MAP kinases have an alternative
activation loop phosphorylation motif SEG, which has only one
phosphorylation site compared to the TXY motif of typical
MAPKs. A recent paper has shown that atypical MAPKs are
phosphorylated on their activation loop by group 1 p21-
activated kinases (PAKs), which leads to their activation.20)
ERK5 is activated by phosphorylation on Thr219 and Tyr221
by MEK5 after which ERK5 autophosphorylates its C-terminal
region,21 including a nuclear localization signal motif that allows
ERK5 to translocate to the nucleus.
ERK5 is a potential drug target for a number of indications
including cancers.22,23 For instance, ERK5 hyperactivation and
overexpression have been observed in particular in a large
fraction of prostate and breast cancer,24 and high ERK5
expression levels have been associated with poor prognosis25 as
well as bone and lymph node metastasis.26,27 In addition, the
ERK5 locus is ampliﬁed in about 50% of all primary HCC
(hepatocellular carcinoma).28 ERK5 is also a key regulator of
tumor angiogenesis which has been demonstrated by the
phenotype of ERK5 knockout mice which display multiple
vascular defects3−5 and by targeted deletion in endothelial cells
resulting in reduced mass and vascular density in xenograft
models.29,30
To establish a structural model for the rational design of
potent and selective inhibitors, we determined the X-ray crystal
structure of the ERK5 kinase domain. In addition, we
characterized the molecular mechanisms determining the
speciﬁcity of selective benzo[e]pyrimido[5,4-b]diazepine-6-
(11H)-one inhibitors (25, 26), a privileged scaﬀold for the
development of selective ATP competitive inhibitors.31,32
■ RESULTS
Structure Determination. ERK5 protein was expressed
and puriﬁed from baculovirus-infected insect cells. Multiple
constructs comprising diﬀerent regions of ERK5 could be used
to produce soluble protein, each with an N-terminal
hexahistidine puriﬁcation tag. Crystals were obtained from a
construct expressing residues 1−397 of human ERK5, which
enabled the ERK5 structure to be determined to 2.8 Å
resolution (Table 1). The electron density for the bound
inhibitor 25 was of good quality and together with the three-
dimensional shape of 25 allowed the inhibitor to be modeled
with conﬁdence. ERK5 residues 47−393 were resolved in the
electron density with the exception of the activation loop
residues 208−214, which were disordered (Figure 1), and
residues 288−292, which form a short loop in the CMGC-
speciﬁc insert. In other MAP kinase structures such as ERK219
phosphorylation of the Thr and Tyr of the activation loop TXY
motif causes the activation loop to fold into an ordered
structure. In the ERK5 structure the activation loop residues
Thr219 and Tyr221, which would be phosphorylated by MEK5
during activation, were not phosphorylated according to
electrospray ionization mass spectrometry, and no sign of
phosphorylation was seen in the electron density. This segment
of the activation loop was instead involved in crystal packing
interactions, including Tyr221 which packs against the inhibitor
25 that is bound to another ERK5 molecule in the crystal
(Supporting Information Figure 1). Therefore, it is unlikely that
phosphorylated, activated ERK5 would crystallize in the same
crystal form as the structure presented here. It is also possible
that variation of the parts of the inhibitor that sit external to the
ATP-binding site would prevent crystallization in this crystal
form. Indeed, the proximity of the symmetry-related Tyr221 to
the methoxy moiety of 25 is most likely the reason that we
obtained crystals with 25 but not with 26 which has instead an
ethoxy moiety.
Structural Similarity to Other CMGC Kinases. The
structure shows the features typical of an ERK family kinase
including the CMGC-speciﬁc insert in the C-terminal lobe of
the kinase domain between αG and αH, and the additional C-
terminal helix that packs above and against the mechanistically
important helix αC (Figure 1). In emphasis of the structural
similarity, despite only 51% sequence identity, the ERK5
structure nevertheless superimposes with the inhibitor-bound
structures of ERK2 (PDB code 2Z7L) and p38β (PDB code
3GP0) with root-mean-square deviations of 1.14 Å over 283
Cα atoms and 1.11 Å over 245 Cα atoms, respectively.
Comparison of the surface charges of ERK5 and ERK2
(Supporting Information Figure 2) reveals that despite the
surfaces containing a large proportion of the nonconserved
residues, there is a relatively similar pattern of surface charge.
ERK5 contains a mostly positively charged substrate binding
region, although there would be modiﬁcation of parts of this
surface upon phosphorylation and ordering of the activation
loop. The MAPK docking peptide region is also quite well
conserved as shown by comparison with the structure of the
complex between ERK2 and a DUSP6 (MKP3) kinase
interaction motif (KIM) docking peptide33 (Supporting
Information Figure 2). The N-terminus of the KIM motif
(R/K)2−3-X1−6-Φ-X-Φ (Φ = hydrophobic residue) binds to a
Table 1. Data Collection and Reﬁnement Statistics for
Cocrystal Structure of ERK5 with 25
PDB code 4B99
space group P41212
no. of molecules in the asymmetric unit 1
unit cell dimensions
a (Å) 95
b (Å) 95
c (Å) 119
α (deg) 90
β (deg) 90
γ (deg) 90
Data Collection
beamline Diamond I24
resolution range (Å)a 74.42−2.80 (2.99−2.80)
unique observationsa 13868 (2466)
average multiplicitya 4.1 (4.1)
completeness (%)a 98.9 (99.2)
Rmerge
a 0.094 (0.711)
mean I/σ(I) a 10.5 (2.4)
Reﬁnement
resolution range (Å) 74.42−2.80
R, Rfree 22.5, 28.7
rms deviation from ideal bond length (Å) 0.006
rms deviation from ideal bond angle (deg) 1.2
aValues within parentheses refer to those of the highest resolution
shell.
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negatively charged region on the back of the kinase domain,
and the hydrophobic residues bind in a groove adjacent to the
kinase hinge region. Both of these surfaces are present in the
ERK5 structure, although the negatively charged region is less
pronounced.
Inhibitor Binding to ERK5. Initial potent and selective
ERK5 inhibitors have been previously identiﬁed by a scaﬀold
expansion of the well-known 2-aminopyrido[2,3-d]pyrimidine
kinase inhibitors leading to the discovery of benzo[e]pyrimido-
[5,4-b]diazepine-6(11H)-ones.34 This privileged inhibitor class
led to the development of a number of highly selective kinase
inhibitors targeting LRRK2, TTK, and Aurora.31,32 Further
optimization of this scaﬀold for LRRK2 and ERK5 is discussed
in a subsequent manuscript46 and led to the discovery of ERK5-
IN-1 (26, Figure 1), a highly selective ERK5 inhibitor. Since 25
diﬀers from 26 only in a solvent-exposed methyl ether, the
following discussion of the ERK5/25 structure applies also to
inhibitor 26.
While the inhibitor 25 binds to ERK5 in the same general
binding mode as previously observed with this inhibitor scaﬀold
(Figure 2), the core forms a much more three-dimensional
shape, with the N-cyclopentyl substituent pointing upward
Figure 1. (A) Structure of ERK5 bound to 25. The N-terminal lobe of the kinase is shown in blue and the C-terminal lobe in green. The activation
loop and αC helix are shown in red, and the CMGC kinase family speciﬁc insert in the C-terminal lobe is shown in pink. The inhibitor ERK5-IN-1
(25) is shown in yellow. Dashed lines represent residues that were not observed in the structure because of disorder. (B) Chemical structures of
inhibitors.
Figure 2. Active site of ERK5 with inhibitor 25 bound. (A) The N-terminal lobe is colored blue. The C-terminal lobe is colored green. The
activation loop and αC helix are colored red, and compound 25 is colored yellow. (B) As in (A) showing the surface of the ERK5 ATP-binding site
around the inhibitor. (C) View from an alternative angle to (A), with the glycine-rich loop (strands β1 and β2) removed for clarity. (D)
Experimental 2mFo − DFc electron density contoured at 1.0σ around the inhibitor from two diﬀerent viewing angles.
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toward the glycine-rich loop and binding against Ile61, and the
6,7,6 ring system curved around Leu189 on β7 in the base of
the ATP-binding site. The inhibitor forms two hydrogen bonds
with the backbone of the kinase hinge region at Met140 and a
hydrogen bond via a water molecule to the backbone nitrogen
of the DFG motif Asp200 and Glu102 from αC (Figure 2A,C).
There are also possibilities for hydrogen bond formation via the
inhibitor’s methoxy group, or amide oxygen, but at the
resolution of the structure the assignment of these cannot be
made unequivocally. The methoxyphenyl moiety binds parallel
to the hinge region residue Ser142 and its peptide bonds to
Glu141 and Asp143 (Figure 2C). Inhibitor 25 has excellent
shape complementarity to the binding site, ﬁlling the majority
of the available space (Figure 2B). The piperidine−piperazine
moiety points out of the ATP binding site and lies adjacent to
the glycine rich loop. However, the positions of the two rings
may be more determined by the crystal packing (Supporting
Information Figure 1), and in solution it is likely that they
would be ﬂexible.
The structure explains why any substituent on the aromatic
ring of the anthranilic acid, in particular at the 3 or 4 position,
signiﬁcantly decreased binding to ERK5. This aromatic ring
binds against the backbone atoms of Gly199 and Asn187
(Figure 2A), and any larger substituent would clash; because of
the N-cyclopentyl substituent, there is insuﬃcient space above
the inhibitor to allow the core 6,7,6 ring system to move
upward to accommodate any additional substituent. The
structure also explains why addition of an N-methyl group
increased binding aﬃnity, as this methyl group forms a
favorable hydrophobic packing with Ile115 (Figure 2C).
Cellular Activity of 26. We used Western blot analysis to
detect ERK5 autophosphorylation in HeLa cells. After
activation by MEK5 phosphorylation on the ERK5 activation
loop, ERK5 autophosphorylates at many other locations,21 and
these many additional phosphorylations cause a mobility shift
of autophosphoryated ERK5 on polyacrylamide gel electro-
phoresis.21 Dose response experiments demonstrated low
nanomolar cellular activity of 26 as judged by the signiﬁcant
dose-dependent reduction of mobility shifted phosphorylated
ERK5 bands from sorbitol stimulated cells. As expected, total
and activated levels of ERK1 and ERK2 remained unaﬀected
indicating selective inhibition of the MEK5/ERK5 but not the
MEK/ERK1/2 pathway (Figure 3A).
Figure 3. Inhibition of ERK5 autophosphorylation in HeLa cells and eﬀect on AP-1 activity. (A) Shown are Western blot analysis of cellular extracts
stimulated by sorbitol using total ERK5 antibodies (top panel), phospho ERK1/2 speciﬁc antibodies (middle panel), and an antibody detecting total
ERK1/2 (lower panel). Phosphorylation of ERK5 is evident by the mobility shift of the ERK5 band. Increasing concentration of 26 leads to
signiﬁcant reduction of ERK5 autophosphorylation levels. (B) Compound 26 inhibits ERK5-mediated AP1 transcriptional activity. The pAP1-
luciferase reporter and pRL-CMV-Renilla plasmids were co-transfected with plasmids encoding for ERK5 and constitutively active MEK5
(MEK5DD) in HEK293 cells. Cells were left alone (control) or treated with the indicated amounts of compound 26 for 24 h, and lysates were
subjected to the dual-luciferase assay. Each value is expressed as % of controls (no inhibitor), as the mean ± SD of three diﬀerent determinations and
normalized using the Renilla values. From the three diﬀerent experiments the EC50 for compound 26 against ERK5 was 4.2 ± 0.69 μM.
Figure 4. Comparison of binding of 25 to ERK5 with that of Mps1-IN-2 to TTK (PDB code 3H9F32). (A) The TTK protein is colored cyan with
the activation loop, and αC helix is colored red. Inhibitor Mps1-IN-2 bound to TTK is colored green. The additional atoms present in 25 that are
not present in Mps1-IN-2 are colored magenta, with the remainder of 25 colored yellow. (B) Surface of the TTK ATP-binding site around the
inhibitor Mps1-IN-2.
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Once activated, ERK5 translocates to the nucleus where it
enhances the transcriptional activity of several transcription
factors, including the AP1 transcriptional complex.10,16 There-
fore, we tested if 26 would inhibit ERK5-mediated AP1
transcriptional activity, to monitor the activity of 26 over one of
ERK5’s cellular functions. An AP1-dependent luciferase gene
reporter assay in HEK293 cells overexpressing ERK5 and a
constitutively active MEK5 (MEK5-DD, S311D/T315D) was
used (Supporting Information Figure 3). Compound 26
completely inhibited the ERK5-mediated AP1 transcriptional
activity at 30 μM and had an EC50 of 4.2 ± 0.7 μM (Figure 3B).
By contrast 24 had an EC50 of >30 μM (Supporting
Information Figure 4).
Comparison of Inhibitor Binding to Mps1-IN-2 Bound
to TTK. The TTK inhibitor Mps1-IN-2 (30, Figure 1B) from
this series adopts a similar general binding arrangement, as seen
in the TTK:30 cocrystal structure (PDB code 3H9F).32
However, the additional aromatic ring that converts the 6,7
ring system into a 6,7,6 system with a terminal anthranilic acid
moiety in our new inhibitor series over 30 causes the inhibitor
to adopt a much less planar shape (Figure 4). The additional
aromatic ring imposes additional conformational restrictions on
the central seven-membered ring such that, because of the N-
cyclopentyl substituent, the observed conformation with the
additional aromatic ring pointing down toward the DFG motif
is the only possible arrangement.
Comparison of the ERK5:25 structure with the TTK:30
structure (Figure 4) shows that the additional aromatic ring
would clash with Ile663 of TTK, explaining why the new series
has lost TTK-binding ability (KINOMEscan data in ref 46).
This comparison shows clearly that these inhibitors require a
small residue before the DFG motif at Gly199. Furthermore,
the N-cyclopentyl substituent on the seven-membered ring
forces the compound into a conformation with the 6−7−6 ring
system curved around Leu189, making that residue essential
too. In the absence of the N-cyclopentyl group the seven-
membered ring could adopt an alternative conformation that
would result in a ﬂatter compound structure or even one in
which the terminal aromatic ring pointed upward toward the
top of the binding site and away from Gly199. KINOMEscan
proﬁling of 25 and 26 compared to compounds without the N-
cyclopentyl group shows that 25 and 26 have a strong binding
preference for kinases that have a small residue before the DFG
motif (ERK5:Gly199), and a Leu on β7 in the base of the ATP-
binding site (Leu189), whereas those without the N-cyclo-
pentyl are more relaxed in their requirements.46
Reasons for the Speciﬁcity of Inhibitors 25 and 26.
Proﬁling of binding data shows that these inhibitors have an
unusual distribution of protein targets, binding strongly only to
a few isolated kinases from across the phylogenetic tree.46 The
N-cyclopentyl-substituted compounds 25 and 26 in particular
select isolated kinases from a subfamily of closely related
members. The non-N-cyclopentyl-substituted compounds,
including LRRK2-IN-1 (15), also partly show this unusual
pattern except with binding to the families of RSK C-terminal
kinase domains, PLKs, and TNK1/TNK2.
As a comparison with the binding of Mps1-IN-2 (30) shows,
a small residue preceding the DFG motif (Gly199 in ERK5)
and Leu in the bottom of the ATP-binding site (Leu189) are
important for binding of the compounds that contain the N-
cyclopentyl substituent on the seven-membered ring. A Gly and
Leu in these positions are commonly found in human protein
kinases; however, among ERKs, JNKs, and p38s, which are
otherwise quite highly related, only ERK5 has this combination
(Figure 5A). For example, ERK3 and ERK4 do have a small
residue (Gly) before the DFG motif but they both have a Phe
Figure 5. Important residues for inhibitor selectivity. (A) Sequence alignment of ERK, JNK, and p38 kinases covering ERK5 Leu189 and Gly199.
Only this combination of Leu and Gly is favorable for binding of the N-cyclopentyl-substituted inhibitors. (B) Sequence alignment of DCAMKLs
covering the loop between αC and β4. An Ile at this position is most favored. (C) Interactions of Ile115 in the ERK5 crystal structure. (D) Sequence
alignment of PLKs as in (A).
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in place of Leu189. LRRK2 has an Ala and a Leu in these
positions, fulﬁlling the favorable criteria for binding. The
compounds without the N-cyclopentyl substituent can bind to
certain kinases that do not fulﬁll these criteria, such as the C-
terminal kinase domains of RSKs/MSKs, MYLK, or MKNK1/
MKNK2 (Supporting Information Figure 5), which explains
the lesser selectivity of 15.
Further illustrating the eﬀect of the N-cyclopentyl substituent
in making Leu189 essential, the binding data against the PLKs
clearly show that the compounds with an N-cyclopentyl
substituent bind only to PLK4, the only isoform with Leu;
the other isoforms that have Phe in this position bind only the
non N-cyclopentyl-substituted compounds (Figure 5D).
The Ile at the back of the pocket (Ile115) is important. This
residue forms a hydrophobic interaction with the N-methyl
group of the inhibitor (Figure 5C). The cross-reacting kinases
DCAMKL1, DCAMKL2, and DCAMKL3 all have favorable
equivalents to Gly199 and Leu189, but only DCAMKL2 has an
Ile equivalent to Ile115; DCAMKL1 and DCAMKL3 have Val
(Figure 5B), and the binding data show that the inhibitors bind
to DCAMKL2 with signiﬁcantly greater aﬃnity. This residue is
strongly conserved as Ile, Val, Leu, or Phe in the kinome;
however, the structure suggests that any hydrophobic residue
other than Ile would not form as good a binding interaction.
The Asp at the end of the hinge region (Asp143) appears to
be important. Across the kinome, a Gly at this position is the
most common residue. However, all kinases bound by this
inhibitor series have a larger residue such as Asp (ERK5), Ser
(LRRK2), Leu (PLK1, PLK3, DCAMKLs, RIPK5), Met
(PLK4), or Val (AURKA). This residue position is presumably
important to sandwich the 2-methoxy-4-carboxamidyl-anilino
moiety against the hinge region to which it forms hydrogen
bonds (Figure 2C).
Overall, these inhibitors appear to achieve their surprising
ERK5 speciﬁcity by relying on steric constraints against speciﬁc
active site residues to prevent inhibitor binding to kinases
otherwise closely related to ERK5; with more distantly related
kinases that could bind the inhibitors without steric hindrance,
the aﬃnities are presumably lower because of each kinase not
having the other residues important for binding aﬃnity. It is
also possible that some kinases are unable to position their
glycine-rich loop to allow enough space for the inhibitor’s N-
cyclopentyl group. Although rotation of a kinase N-lobe relative
to the C-lobe is commonly seen when binding to diverse
inhibitors, the rigid three-dimensional core of this inhibitor
series couples the rotation of the N-lobe to the hydrogen
bonding on the hinge region, while the inhibitor’s orientation
relative to the C-lobe is ﬁxed by the interactions with Leu189
(Figure 6); it may be that some kinases cannot appropriately
position their glycine-rich loops while maintaining the hinge
hydrogen bonds.
Among the weaker bound kinases there are nevertheless
some outliers that are not so easily explained, such as TNK1/
TNK2 which have favorable equivalents to Gly199, Leu189,
and Ile115, except TNK1 which has a Val instead of Ile115; but
it is TNK1 that has the slightly higher binding aﬃnity
compared to TNK2 (data in ref 46). However, overall there
are no strongly bound intrasubfamily selectivities that are not
explained by the criteria above.
A fuller sequence alignment of kinases relevant to the
discussion here can be found in the Supporting Information.
Previously the kinase inhibitors BIX02188 and BIX02189
have been reported by Boehringer Ingelheim as MEK5
inhibitors but then also shown to have strong binding to
ERK5, as well as good selectivity for MEK5 and ERK5.35 These
inhibitors are based on a diﬀerent scaﬀold to 25/26 with an
indolin-2-one core. BIX02188 and BIX02189 diﬀer by the
addition of two methyl groups to the 6-carboxamide moiety in
BIX02189. BIX02188 and BIX02189 have IC50 values against
ERK5 of 810 and 59 nM, respectively.35 However, no
experimental binding mode of these inhibitors has been
reported.
Although BIX02188 and BIX02189 have good selectivity for
MEK5 and ERK5 among other MAPK family members, they
also potently inhibit various tyrosine kinases (TKs).35 This is to
be expected, since the 3-substituted indolin-2-ones have been
seen in a variety of TK-targeting inhibitors such as sunitinib
(SU11248, Pﬁzer Inc.). Compared to 25/26, BIX02188 and
BIX02189 have greater conformational ﬂexibility, and it may be
that a more rigid derivative of the BIX02189 scaﬀold could be a
starting point for more speciﬁc inhibitors against various
kinases. Both possible modes of binding to ERK5 suggest that
joining the phenyl and 3-((dimethylamino)methyl)aniline
moieties to form a macrocycle might be the basis of a useful
chemical series.
■ CONCLUSION
The structure of ERK5 helps to explain the observed structure−
activity relationships of known ERK5 inhibitors, identiﬁes
active site features speciﬁc to ERK5, and provides a template to
aid in the design of additional inhibitor series.
■ MATERIALS AND METHODS
Cloning. DNA for MAPK7 isoform 1 residues 1−397 (gi|
20986497) was PCR ampliﬁed and subcloned into an in-house
pFASTBAC-based vector pFB-LIC-Bse36 from DNA in the Mamma-
lian Gene Collection (IMAGE consortium clone identiﬁer 4111084),
using ligation-independent cloning. The resulting plasmid was used to
generate a recombinant baculovirus by the Bac-to-Bac method
(Invitrogen). The resulting baculovirus expressed the kinase domain
of ERK5, with an N-terminal hexahistidine tag and TEV (tobacco etch
virus) protease tag cleavage site (extension MGHHHHHH-
SSGVDLGTENLYFQ*S-).
Expression and Puriﬁcation. The baculovirus was used to infect
3 L of Spodoptera frugiperda cells (Sf9) in suspension culture at a
density of 2 × 106 cells/mL in Insect-XPRESS medium (Lonza). The
ﬂasks were shaken at 27 °C for 48 h. The cells were harvested by
centrifugation at 1000g, resuspended in 45 mL of lysis buﬀer (50 mM
Tris, pH 7.8, 200 mM NaCl, 20 mM imidazole, 0.5 mM TCEP, 1:2000
Figure 6. Three-dimensional core of the inhibitor selects a speciﬁc
conformation of the kinase with respect to rotation of the N-lobe
against the C-lobe.
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dilution of Sigma protease inhibitor cocktail), and frozen at −20 °C
until further use. The frozen cell pellet was thawed, and the cells were
lysed by sonication. Polyethyleneimine (PEI) was added to a
concentration of 0.1%, and the insoluble debris was removed by
centrifugation.
The supernatant was bound to 6 mL of Ni Sepharose resin (GE
Healthcare) and washed with 50 mL of lysis buﬀer, 50 mL of lysis
buﬀer containing 40 mM imidazole and 1 M NaCl, and 50 mL of lysis
buﬀer containing 60 mM imidazole. Finally the resin was eluted with
36 mL of lysis buﬀer containing 250 mM imidazole. The 60 and 250
mM imidazole elution fractions were combined, and tobacco etch virus
(TEV) protease was added. After overnight incubation at 4 °C the
protein was concentrated by ultraﬁltration. The concentrated protein
was injected onto an S200 16/60 gel ﬁltration column (GE
Healthcare) in 20 mM Tris, pH 7.8, 200 mM NaCl, 0.5 mM TCEP
(GF buﬀer). Fractions containing ERK5 were pooled and passed
through 1 mL of Ni Sepharose resin. The resin was eluted with 5 mL
of GF buﬀer, then 5 mL of GF buﬀer containing 10 mM and then 20
mM imidazole. The ﬂow-through and elution fractions were
combined, concentrated by ultraﬁltration, and injected a second time
onto an S200 16/60 gel ﬁltration column in GF buﬀer. Fractions
containing ERK5 were pooled.
Protein identity was conﬁrmed by mass spectrometry under
denaturing conditions (expected 44 942.7 Da, observed 44 943.7 Da).
Crystallization and Data Collection. Inhibitor 25 was added to
the protein such that the ﬁnal inhibitor concentration after subsequent
concentration of the sample would be 1 mM. The sample was
concentrated by ultraﬁltration to a protein concentration of 12.6 mg/
mL (measured by absorbance at 280 nm).
Crystals were obtained using the sitting drop vapor diﬀusion
method at 4 °C. Crystals grew from a mixture of 75 nL of protein and
75 nL of a well solution containing 0.05 M CaCl2, 0.1 M MES, pH 6.0,
20% PEG 6000, 10% ethylene glycol. Crystals were cryoprotected
using the well solution supplemented to 25% ethylene glycol and ﬂash-
frozen in liquid nitrogen.
X-ray diﬀraction data was collected at the Diamond synchrotron,
beamline I24. Data collection statistics can be found in Table 1.
Structure Determination. The diﬀraction data were indexed and
integrated using MOSFLM37 and scaled using AIMLESS.38 The
structure was solved by molecular replacement using Phaser39 and the
structure of p38β (PDB code 3GC9)40 as a search model. There was
one molecule in the asymmetric unit. The model was built using
Coot41 and reﬁned with REFMAC5.42 Rebuilding and reﬁnement
(including reﬁnement of TLS parameters and addition of atoms for the
inhibitor) resulted in the ﬁnal model. Atomic restraints for the
inhibitor were generated using PRODRG,43 and the model was
validated using MolProbity.44
Western Blot Analysis. HeLa cells were maintained in DMEM
supplemented with 10% FBS, 2 mM L-glutamine, 50 U/mL penicillin
G, and 50 μg/mL streptomycin. Before use HeLa cells were serum
starved for 16 h in DMEM (Dulbecco’s modiﬁed Eagle medium)
supplemented with 2 mM L-glutamine, 50 U/mL penicillin G, and 50
μg/mL streptomycin. HeLa cells were then incubated with ERK5-IN-1
at the indicated concentrations for 1 h prior to stimulation with 0.5 M
sorbitol for 30 min. Cells were lysed in Triton lysis buﬀer (50 mM
Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM sodium
orthovanadate, 50 mM sodium ﬂuoride, 1 mM sodium pyrophosphate,
0.27 M sucrose, 1 μM microcystin-LR, 1% (v/v) Triton X-100, 0.1%
(v/v) 2-mercaptoethanol) and 20 μg of protein loaded per well.
Samples were run on 8% polyacrylamide gels using standard methods.
Proteins were transferred onto nitrocellulose membranes and speciﬁc
proteins detected by immunoblotting. Total ERK5 antibody was
obtained from Sigma, and total ERK1/2 and phospho ERK1/2 were
purchased from Cell Signaling Technology. HRP-conjugated secon-
dary antibodies were purchased from Pierce (Cheshire, U.K.), and
detection was performed using the ECL reagent from Amersham
Biosciences.
AP1-Dependent Luciferase Gene Reporter Assay. DNA
Constructs. We used the pEBG-2T vector encoding for GST-tagged
full-length human ERK5 and a pCMV plasmid encoding HA-tagged
human MEK5-DD.45 AP1-luciferase vector was purchased from
Stratagene, and pRL-CMV-Renilla was purchased from Promega.
Reporter Luciferase Assay. HEK293 cells were cultured at 37 °C
under humidiﬁed air (5% CO2), using DMEM supplemented with
10% FBS (fetal bovine serum) and penicillin/streptomycin antibiotics.
Cells were transfected using PEI (Warrington, U.S.). HEK293 cells
cultured in 12-well plates were transfected with 500 ng of DNA, which
contained plasmids encoding for AP-1-driven luciferase reporter (150
ng), Renilla (50 ng), ERK5 (100 ng), and MEK5-DD (200 ng). Three
hours after transfection, the medium was changed and inhibitor
compounds (dissolved in DMSO) were added at the indicated ﬁnal
concentrations. The concentration of DMSO in the culture medium
did not exceed 0.3%. At 36 h later, luciferase activity assay was
performed using the dual-luciferase reporter assay kit (Promega) in a
Clarity luminescence microplate reader (BioTek Instruments). Results
are presented as AP1-luciferase values normalized against Renilla
luciferase activity. Data were obtained from triplicate determinations
from three diﬀerent experiments and analyzed by nonlinear regression
using GraphPad software (GraphPad Software Inc.).
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